

The Teva Support Solutions® Patient Support Program

Teva is proud to offer the Teva Support Solutions® Patient Support Program to rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients who have been prescribed PrTRUXIMA®.



TRUXIMA® in combination with methotrexate is indicated to reduce signs and symptoms in adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor inhibitor therapies.^{1*}



TRUXIMA® in combination with glucocorticoids is indicated for the induction of remission in adult patients with severely active GPA (also known as Wegener's granulomatosis) and MPA.^{1*}

The Teva Support Solutions® Patient Support Program has professional case managers who can support your patients on their treatment journeys.



The enrolment process is quick and easy. Simply complete one enrolment form per patient and fax them to **1-833-981-2254** or email them to **tss.info@truximacanada.com**. We will take care of the rest!

* Indications have been granted on the basis of similarity between TRUXIMA® and the reference biologic drug Rituxan®.



A welcome call

Within one business day of receiving each of your patients' enrolment forms, our case managers will call them to welcome them into the program.



Educational materials

Then, we will send a TRUXIMA® welcome package of valuable information to each of your patients to help them get started with their treatment journeys.



Open discussions

Case managers will be available for your patients from 8 AM to 8 PM Eastern Time, Monday to Friday, to provide them with support, knowledge and answers related to their treatments, including questions they may have about TRUXIMA®.



Reimbursement services

Case managers can also work with your patients and their respective insurance providers to assess coverage options for TRUXIMA®.



Financial assistance

In some cases, the Teva Support Solutions® Patient Support Program can provide personalized financial solutions to help your patients get started with their TRUXIMA® treatments.



Medical updates

Our case managers will make sure to provide you with relevant updates on your patients' health status along the way and help to establish proactive follow-up schedules.



If you have any questions about the Teva Support Solutions® Patient Support Program, please call our toll-free number at **1-877-714-2469**, any time between 8 AM and 8 PM Eastern Time, Monday to Friday. You can also email us at tss.info@truximacanada.com at your convenience.

For more information: Please consult the Product Monograph at tevacanada.com/globalassets/canada-scs-files---global/product-monographs/truxima-product-monograph_en.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration (administered as an intravenous [IV] infusion through a dedicated line, not administered as an IV push or bolus) and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Reference: 1. TRUXIMA® Product Monograph. Teva Canada Limited. August 22, 2024.

teva | Canada

Brands. Generics. **Biosimilars.**

Rituxan® is a registered trademark of IDEC Pharmaceuticals Corporation, used under license.

P[®]TRUXIMA® is a registered trademark of Celltrion Inc.

© 2025 Teva Canada Innovation G.P. – S.E.N.C.

Montreal, Quebec, H2Z 1S8 TRUX-CA-00136E 02/2025



Truxima
Rituximab for Injection
10 mg/mL Intravenous Infusion

**TEVA SUPPORT
SOLUTIONS**
Patient Support Program